US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

These findings provide a potential new, effective, disease-specific treatment option for lichen planus and therapeutic targets for other inflammatory diseases." Aaron R. Mangold, M.D., senior ...

Future Microbiol. 2010;5(1):15-22. The ocular and genital mucosa are key players in regulation of herpes simplex virus (HSV) susceptibility and recurrent disease. Prophylactic and therapeutic ...

Biopsy showed lichen simplex chronicus. There are no clinical manifestations ... Upper thighs, arm, and trunk responded extremely well after 10 treatments of UVB (about 1 month).

Nail biopsy: If lichen planus may be affecting one or more of your nails, your dermatologist will remove a small sample from the suspected area, so that it can be examined under a microscope. Not ...

Nail biopsy: If lichen planus may be affecting one or more of your nails, your dermatologist will remove a small sample from the suspected area, so that it can be examined under a microscope. Not ...